Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. H. Prince
A Prospective Study of the Separate Predictive Capabilities of 18[f]-FDG-Pet and Molecular Response in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma Following Treatment With Iodine-131-Rituximab Radio-Immunotherapy
Haematologica
Hematology
Related publications
[18 F]-FDG PET/CT in the Staging and Management of Indolent Lymphoma: A Prospective Multicenter PET Registry Study
Cancer
Cancer Research
Oncology
Predictive Potential of FDG-PET/CT for Histological Transformation in Patients With Indolent Lymphoma
Advances in Molecular Imaging
Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 With and Following Rituximab in Patients With Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma
Haematologica
Hematology
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma
British Journal of Haematology
Hematology
Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine
Hepatology
Medicine
Hepatology
Fact Sheet About Interim and End-Of-Treatment 18 F-FDG PET/CT in Lymphoma
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
